Gilead Sciences (GILD) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$30.5B

Revenue (quarter)

$7.8B

Revenue growth (year over year)

+10.18%

Gross profit (trailing twelve months)

$24.2B

Gross margin

79.59%

Net income (trailing twelve months)

−$3.2B

Net income (quarter)

−$10.5B

Net income growth (year over year)

−635.51%

Net margin

−10.64%

Return on equity

−20.57%

EPS (trailing twelve months)

−$2.61

Book value per share

$9.53

P/E (trailing twelve months)

—

Price to book

16.21

Debt to assets

76.21%

Payout ratio

46.14%

Dividend yield

2.12%

Company profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

• Is Gilead Sciences (GILD) profitable?

  No. Gilead Sciences reported a net loss of $3.2B over the trailing twelve months.

• How much revenue does Gilead Sciences (GILD) make?

  Gilead Sciences generated $30.5B in revenue over the trailing twelve months, up 10.18% year over year.

• How do I buy stock in Gilead Sciences (GILD)?

  GILD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.